Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the anticipated trial results involving I-O, TKIs and biomarkers in renal cell carcinoma (RCC).
Most Anticipated Trial Results Regarding Biomarkers in RCC
Tian Zhang , MD, Assistant Professor of Medicine, Duke Cancer Institute, explains the anticipated trial results involving I-O, TKIs and biomarkers in renal cell carcinoma (RCC).